Search Results - "Wajsbrot, Dalia B"

Effects of desvenlafaxine versus placebo on MDD symptom clusters: A pooled analysis by Katzman, Martin A, Wang, Xuemei, Wajsbrot, Dalia B, Boucher, Matthieu

“…Background: Major depressive disorder is characterized by the presence of at least five of nine specific symptoms that contribute to clinically significant…”
Get full text

Clustering patients by depression symptoms to predict venlafaxine ER antidepressant efficacy: Individual patient data analysis by Kato, Masaki, Asami, Yuko, Wajsbrot, Dalia B., Wang, Xuemei, Boucher, Matthieu, Prieto, Rita, Pappadopulos, Elizabeth

“…To identify clusters of patients with major depressive disorder (MDD) based on the baseline 17-item Hamilton Rating Scale for Depression (HAM-D17) items and to…”
Get full text

Efficacy of venlafaxine extended release in major depressive disorder patients: effect of baseline anxiety symptom severity by Lyndon, Gavin J., Prieto, Rita, Wajsbrot, Dalia B., Allgulander, Christer, Bandelow, Borwin

“…Effects of baseline anxiety on the efficacy of venlafaxine extended release versus placebo were examined in a post hoc pooled subgroup analysis of 1573…”
Get full text

Trajectories of Function and Symptom Change in Desvenlafaxine Clinical Trials: Toward Personalized Treatment for Depression by Zilcha-Mano, Sigal, Wang, Xuemei, Wajsbrot, Dalia B., Boucher, Matthieu, Fine, Stuart A., Rutherford, Bret R.

“…Heterogeneity has been documented in trajectories of symptom change during antidepressant treatment for major depressive disorder (MDD). It is unclear whether…”
Get full text

Predictors of functional response and remission with desvenlafaxine 50 mg and 100 mg: a pooled analysis of randomized, placebo-controlled studies in patients with major depressive disorder by Soares, Claudio N, Wajsbrot, Dalia B, Boucher, Matthieu

“…The value of early functional improvement at week 2 for predicting subsequent functional outcomes at week 8 was assessed in a pooled analysis of patients with…”
Get full text

Speed of Improvement in Symptoms of Depression With Desvenlafaxine 50 mg and 100 mg Compared With Placebo in Patients With Major Depressive Disorder by Katzman, Martin A, Nierenberg, Andrew A, Wajsbrot, Dalia B, Meier, Ellen, Prieto, Rita, Pappadopulos, Elizabeth, Mackell, Joan, Boucher, Matthieu

“…This post hoc analysis examined the time point at which clinically significant improvement in major depressive disorder (MDD) symptoms occurs with…”
Get full text

Effect of desvenlafaxine 50 mg and 100 mg on energy and lassitude in patients with major depressive disorder: A pooled analysis by Lam, Raymond W, Wajsbrot, Dalia B, Meier, Ellen, Pappadopulos, Elizabeth, Mackell, Joan A, Boucher, Matthieu

“…Nine randomized, double-blind, placebo-controlled studies of major depressive disorder were pooled to evaluate the effects of desvenlafaxine 50- and 100-mg/d…”
Get full text

An epidemiological study to assess the prevalence of diabetic peripheral neuropathic pain among adults with diabetes attending private and institutional outpatient clinics in South Africa by Jacovides, Andrew, Bogoshi, Mampedi, Distiller, Larry A, Mahgoub, Ehab Y, Omar, Mahomed KA, Tarek, Ismail A, Wajsbrot, Dalia B

“…Objective To determine the prevalence of diabetic peripheral neuropathic pain (DPNP) among South African adults with type 1 or type 2 diabetes. Methods This…”
Get full text

Safety and immunovirologic outcomes with maraviroc combination regimens in patients with a history of past treatment failures and virologic resistance in Brazil: an open-label, multicenter phase 3b study by Furtado, Juvencio, Madruga, José V, Bicudo, Eliana L, da Eira, Margareth, Lopes, Max I B F, Netto, Eduardo M, Santini-Oliveira, Marília, Leite, Olavo H M, Machado, Alcyone A, Tupinambas, Unaí, de Andrade Neto, José L, Lima, Maria P J S, Pedro, Rogério de Jesus, Miranda, Antônio F B, Lewi, David S, Santos, Breno R, Portsmouth, Simon, Wajsbrot, Dalia B, Cassoli, Lourenia M

“…Maraviroc is a first-in-class chemokine coreceptor type-5 (CCR5) antagonist with demonstrated immunovirologic activity in treatment-experienced (TE) patients…”
Get more information

Trajectories of Function and Symptom Change in Desvenlafaxine Clinical Trials: Toward Personalized Treatment for Depression by Zilcha-Mano, Sigal, Wang, Xuemei, Wajsbrot, Dalia B., Boucher, Matthieu, Fine, Stuart A., Rutherford, Bret R.

Get full text